Elhage A - Search Results

1

Defining benefit: Clinically and biologically meaningful outcomes in the next-generation Alzheimer's disease clinical care pathway.

Elhage A, Cohen S, Cummings J, van der Flier WM, Aisen P, Cho M, Bell J, Hampel H. Elhage A, et al. Alzheimers Dement. 2024 Dec 19. doi: 10.1002/alz.14425. Online ahead of print. Alzheimers Dement. 2024. PMID: 39697158 Review.

2

Hampel H, Elhage A, Cho M, Nicoll JA, Atri A. Hampel H, et al. Among authors: elhage a. Neurodegener Dis Manag. 2024;14(3-4):51-62. doi: 10.1080/17582024.2024.2343539. Epub 2024 Jun 3. Neurodegener Dis Manag. 2024. PMID: 38949171 Free PMC article.

3

Graft-versus-leukaemia immunity is retained following treatment with post-transplant cyclophosphamide alone or combined with tocilizumab in humanised mice.

Sligar C, Reilly E, Cuthbertson P, Vine KL, Bird KM, Elhage A, Alexander SI, Sluyter R, Watson D. Sligar C, et al. Among authors: elhage a. Clin Transl Immunology. 2024 Mar 15;13(3):e1497. doi: 10.1002/cti2.1497. eCollection 2024. Clin Transl Immunology. 2024. PMID: 38495918 Free PMC article.

4

Post-Transplant Cyclophosphamide Combined with Brilliant Blue G Reduces Graft-versus-Host Disease without Compromising Graft-versus-Leukaemia Immunity in Humanised Mice.

Cuthbertson P, Button A, Sligar C, Elhage A, Vine KL, Watson D, Sluyter R. Cuthbertson P, et al. Among authors: elhage a. Int J Mol Sci. 2024 Feb 1;25(3):1775. doi: 10.3390/ijms25031775. Int J Mol Sci. 2024. PMID: 38339054 Free PMC article.

5

A Species-Specific Anti-Human P2X7 Monoclonal Antibody Reduces Graft-versus-Host Disease in Humanised Mice.

Elhage A, Cuthbertson P, Sligar C, Watson D, Sluyter R. Elhage A, et al. Pharmaceutics. 2023 Aug 31;15(9):2263. doi: 10.3390/pharmaceutics15092263. Pharmaceutics. 2023. PMID: 37765233 Free PMC article.

6

Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics.

Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Hampel H, et al. Among authors: elhage a. Brain. 2023 Nov 2;146(11):4414-4424. doi: 10.1093/brain/awad188. Brain. 2023. PMID: 37280110 Free PMC article. Review.

7

Tocilizumab increases regulatory T cells, reduces natural killer cells and delays graft-versus-host disease development in humanized mice treated with post-transplant cyclophosphamide.

Sligar C, Cuthbertson P, Miles NA, Adhikary SR, Elhage A, Zhang G, Alexander SI, Sluyter R, Watson D. Sligar C, et al. Among authors: elhage a. Immunol Cell Biol. 2023 Aug;101(7):639-656. doi: 10.1111/imcb.12652. Epub 2023 May 16. Immunol Cell Biol. 2023. PMID: 37191045

8

Purinergic signalling in graft-versus-host disease.

Sluyter R, Cuthbertson P, Elhage A, Sligar C, Watson D. Sluyter R, et al. Among authors: elhage a. Curr Opin Pharmacol. 2023 Feb;68:102346. doi: 10.1016/j.coph.2022.102346. Epub 2023 Jan 10. Curr Opin Pharmacol. 2023. PMID: 36634595 Review.

9

6-Furopyridine Hexamethylene Amiloride Is a Non-Selective P2X7 Receptor Antagonist.

Cuthbertson P, Elhage A, Al-Rifai D, Sophocleous RA, Turner RJ, Aboelela A, Majed H, Bujaroski RS, Jalilian I, Kelso MJ, Watson D, Buckley BJ, Sluyter R. Cuthbertson P, et al. Among authors: elhage a. Biomolecules. 2022 Sep 16;12(9):1309. doi: 10.3390/biom12091309. Biomolecules. 2022. PMID: 36139148 Free PMC article.

10

Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Elhage A, Sligar C, Cuthbertson P, Watson D, Sluyter R. Elhage A, et al. Biosci Rep. 2022 Sep 30;42(9):BSR20211986. doi: 10.1042/BSR20211986. Biosci Rep. 2022. PMID: 35993192 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

59 results

Search Page

Filters